<DOC>
	<DOCNO>NCT00127855</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity 3 formulation Hib-MenCY-TT vaccine compare 2 control group receive licensed meningococcal serogroup C conjugate vaccine and/or license Hib conjugate vaccine administer 2 , 4 , 6 month age . Antibody persistence immune response polysaccharide vaccine booster additionally assess 11 14 month age .</brief_summary>
	<brief_title>Dose Ranging Study Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY ( Hib-MenCY-TT ) Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<criteria>Inclusion criterion : A male female , include , 6 12 week ( 4290 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Vaccinated hepatitis B birth . Born gestation period 36 42 week . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth Any chronic drug therapy continue study period . Planned administration/ administration vaccine foreseen study protocol within one month first dose vaccine ( ) . Previous vaccination diphtheria , tetanus , pertussis , polio , N. meningitidis serogroups C Y , Haemophilus influenzae type b Streptococcus pneumoniae . History known exposure diphtheria , tetanus , pertussis , polio , invasive disease due N. meningitidis serogroups C Y , Haemophilus influenzae type b Streptococcus pneumoniae . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Invasive bacterial disease cause Hib</keyword>
	<keyword>Neisseria meningitidis serogroups C &amp; Y</keyword>
</DOC>